These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 3145187)

  • 21. The effect of bromocriptine on gonadotropin and steroid secretion in polycystic ovarian disease.
    Steingold KA; Lobo RA; Judd HL; Lu JK; Chang RJ
    J Clin Endocrinol Metab; 1986 May; 62(5):1048-51. PubMed ID: 2937800
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Possible mechanisms of the interaction between gonadotropins and prolactin in an experimental hyperprolactinemia model].
    Tresguerres JA; Esquifino AI
    Acta Physiol Lat Am; 1983; 33(3):257-74. PubMed ID: 6424409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Polycystic ovarian disease.
    Duignan NM
    Br J Obstet Gynaecol; 1976 Aug; 83(8):593-602. PubMed ID: 133709
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The interrelationships between prolactin and thyrotrophin secretion following dopaminergic blockage in patients with mild hyperprolactinaemia without any demonstrable pituitary tumour.
    Spitz IM; Haas M; Trestian S; Zylber-Haran E; Shilo S
    Clin Endocrinol (Oxf); 1983 Sep; 19(3):285-94. PubMed ID: 6414745
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrinological environment with regard to the number of microcysts in patients with polycystic ovary syndrome.
    Yoshino K; Takahashi K; Eda Y; Okada S; Kitao M
    Hum Reprod; 1992 Oct; 7(9):1201-4. PubMed ID: 1478997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of ovarian surgery on the dopaminergic and opioidergic control of gonadotropin and prolactin secretion in women with polycystic ovarian disease.
    Szilágyi A; Hole R; Keckstein J; Rossmanith WG
    Gynecol Endocrinol; 1993 Sep; 7(3):159-66. PubMed ID: 8291452
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased dopamine turnover in women with polycystic ovary syndrome.
    Segos C; Markianos M; Aravantinos D
    Eur J Obstet Gynecol Reprod Biol; 1989 Dec; 33(3):229-34. PubMed ID: 2513236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of pulsatile secretion of gonadotropin and prolactin in women with normal menstrual cycle, secondary amenorrhea and polycystic ovary syndrome (PCOS).
    Lin KC; Lee JN
    Kaohsiung J Med Sci; 1998 Feb; 14(2):61-7. PubMed ID: 9542361
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Responses of serum gonadotrophins to LH-releasing hormone and oestrogens in Japanese women with polycystic ovaries.
    Aono T; Miyazaki M; Miyake A; Kinugasa T; Kurachi K; Matsumoto K
    Acta Endocrinol (Copenh); 1977 Aug; 85(4):840-9. PubMed ID: 196471
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of laparoscopic multiple punch resection of the ovary on hypothalamo-pituitary axis in polycystic ovary syndrome.
    Sumioki H; Utsunomyiya T; Matsuoka K; Korenaga M; Kadota T
    Fertil Steril; 1988 Oct; 50(4):567-72. PubMed ID: 2971578
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hyperprolactinemia in polycystic ovary syndrome.
    Luciano AA; Chapler FK; Sherman BM
    Fertil Steril; 1984 May; 41(5):719-25. PubMed ID: 6425087
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibitory effect of bromocriptine treatment on luteinizing hormone secretion in polycystic ovary syndrome.
    Falaschi P; Rocco A; del Pozo E
    J Clin Endocrinol Metab; 1986 Feb; 62(2):348-51. PubMed ID: 3510225
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Correlation of LH and prolactin pulses in normoprolactinemic women with ovulatory disturbances and variation of LH and FSH pulses and secreting capacity by administration of bromocriptine in the same cases].
    Kato K; Watanabe R; Ito E; Sakamoto T; Morishima M; Hoshino K; Tanaka M; Tadokoro N
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Dec; 38(12):2241-50. PubMed ID: 3100705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bromocriptine treatment in anovulation with decreased ratio of follicle stimulating hormone to luteinizing hormone and with hyperandrogenism.
    Suginami H; Kuroda G; Yano K; Kitagawa H; Matsuura S
    Endocrinol Jpn; 1988 Feb; 35(1):47-55. PubMed ID: 2969329
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the inappropriate gonadotropin secretion in polycystic ovary syndrome.
    Rebar R; Judd HL; Yen SS; Rakoff J; Vandenberg G; Naftolin F
    J Clin Invest; 1976 May; 57(5):1320-9. PubMed ID: 770505
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
    van der Westhuizen S; van der Spuy ZM
    Ultrasound Obstet Gynecol; 1996 May; 7(5):335-41. PubMed ID: 8774098
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The acute effects of a dopamine antagonist (domperidone) on luteinising hormone, follicule stimulating hormone, prolactin and thyrotrophin secretion in polycystic ovarian syndrome: differential effect of ovulation.
    Murdoch AP; Dunlop W; Kendall-Taylor P; Watson MJ
    Clin Endocrinol (Oxf); 1984 Dec; 21(6):611-9. PubMed ID: 6439439
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of polycystic ovarian changes and polycystic ovary syndrome in premenopausal women with treated type 2 diabetes mellitus.
    Kelestimur F; Unluhizarci K; Baybuga H; Atmaca H; Bayram F; Sahin Y
    Fertil Steril; 2006 Aug; 86(2):405-10. PubMed ID: 16762349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hyperprolactinemia and disorders of the menstrual cycle].
    Topalski-Fistes N; Bujas M; Maticki-Sekulić M; Suvacarev S
    Med Pregl; 1999; 52(3-5):156-61. PubMed ID: 10518402
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Episodic luteinizing hormone release in hyperprolactinemic women.
    Wiebe RH; Handwerger S; Soules M
    Fertil Steril; 1986 Apr; 45(4):483-8. PubMed ID: 3082682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.